Skip to main content


Generic name: tildrakizumab [ TIL-dra-KIZ-ue-mab ]
Brand name: Ilumya
Dosage form: subcutaneous solution (100 mg/mL)
Drug class: Interleukin inhibitors

Medically reviewed by on Feb 8, 2024. Written by Cerner Multum.

What is tildrakizumab?

Tildrakizumab reduces the effects of a substance in the body that can cause inflammation.

Tildrakizumab is used to treat moderate to severe psoriasis in adults.

Tildrakizumab may also be used for purposes not listed in this medication guide.

What are the lofexidine side effects of tildrakizumab?

Get emergency medical help if you have signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.

You may get infections more easily, even serious or fatal infections. Call your doctor right away if you have signs of infection such as:

Common side effects of tildrakizumab may include:

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.


Tildrakizumab affects your immune system. You may get infections more easily. Call your doctor if you have a fever, chills, aches, cough, shortness of breath, skin sores, diarrhea, weight loss, or burning when you urinate.

Before taking this medicine

You should not be treated with tildrakizumab if you are allergic to it.

Tell your doctor if you have a chronic infection, or if you are scheduled to receive any vaccine.

Tell your doctor if you have ever had tuberculosis or if anyone in your household has tuberculosis.

It is not known whether tildrakizumab will harm an unborn baby. Tell your doctor if you are pregnant or plan to become pregnant.

It may not be safe to breast-feed while using this medicine. Ask your doctor about any risk.

Tildrakizumab is not approved for use by anyone younger than 18 years old.

How is tildrakizumab given?

Before you start treatment with tildrakizumab, your doctor may perform tests to make sure you do not have tuberculosis or other infections.

Tildrakizumab is injected under the skin.

A healthcare provider will give you this injection.

Tildrakizumab dosing information

Usual Adult Dose for Plaque Psoriasis:

100 mg subcutaneously at Weeks 0 and 4, and every 12 weeks thereafter

-Evaluate patients for tuberculosis (TB) infection prior to initiating therapy.

Use: For adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy

What happens if I miss a dose?

Call your doctor for instructions if you miss an appointment for your tildrakizumab injection.

What happens if I overdose?

Seek emergency medical attention or call the Poison Help line at 1-800-222-1222.

What should I avoid while receiving tildrakizumab?

Do not receive a "live" vaccine while using tildrakizumab. The vaccine may not work as well and may not fully protect you from disease. Live vaccines include measles, mumps, rubella (MMR), polio, rotavirus, typhoid, yellow fever, varicella (chickenpox), and zoster (shingles).

What other drugs will affect tildrakizumab?

Other drugs may affect tildrakizumab, including prescription and over-the-counter medicines, vitamins, and herbal products. Tell your doctor about all your current medicines and any medicine you start or stop using.

Popular FAQ

There are a number of differences between Skyrizi and Ilumya:

  • Ilumya was FDA approved in 2018 and Skyrizi was FDA approved in 2019.
  • Ilyumya is a brand name for tildrakizumab and Skyrizi is a brand name for risankizumab
  • The dose of Skyrizi is 150mg, but because each injection only contains 75mg, two injections must be given per dose. The dose of Ilumya is 100mg, and each injection contains 100mg therefore only one injection needs to be given each time
  • Ilumya needs to be administered by a healthcare professional; however, patients prescribed Skyrizi can be taught how to self-administer it at home
  • Skyrizi is also approved to treat adults with active psoriatic arthritis (PsA).
Continue reading

Ilumya is not approved by the FDA to treat psoriatic arthritis, but studies for this use are ongoing. Illumya is only approved to treat plaque psoriasis at this time. Your doctor may decide, based on their medical judgement, to prescribe Ilumya off-label for other conditions. Continue reading

There have been few comparative trials comparing Ilumya to other biologics used for the treatment of moderate to severe plaque-type psoriasis. The joint AAD and NPF guidelines conclude that all 11 biologics have grade A evidence for efficacy as monotherapy in plaque psoriasis and a person’s medical and social should be taken into account when choosing a biologic. Certain biologics may be preferred in people who are overweight because they use weight-based dosing (such as infliximab or Stelara), whereas others may be preferred in those with poor compliance because they are dosed every 12 weeks (such as Stelara, Skyrizi or Ilumya). Continue reading

It takes approximately 12 weeks for Ilumya to start working with nearly 60% of people experiencing a 75% reduction in the severity of their psoriasis within that time; however, it may take over a year for the full benefits to be seen. Continue reading

Ilumya affects the immune system by blocking the effects of IL-23, a proinflammatory cytokine that helps to regulate inflammation associated with autoimmune conditions, such as psoriasis) as well as bacterial and viral infections. By blocking the effects of IL-23, Ilumya increases your risk of developing infections and may cause the reactivation of latent tuberculosis; however, the risk of serious infections is low (0.3%) and the same as placebo. Continue reading

More FAQ

View more FAQ

Further information

Remember, keep this and all other medicines out of the reach of children, never share your medicines with others, and use this medication only for the indication prescribed.

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.